(Q)-Twist analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer

被引：0
|
作者：
Chung, H. C.
Bang, Y.
Van Cutsem, E.
Kang, Y.
Hamamoto, Y.
Moiseyenko, V.
Gotovkin, E.
Urspruch, A.
Ducournau, P.
机构：
[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[3] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium
[4] Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan
[6] Inst Oncol, Dept Biotherapy & BMT, St Petersburg, Russia
[7] Ivanovo Reg Oncol Dispensary, Ivanovo, Russia
[8] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4048
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [42] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results.
    Kang, Y.
    Kang, W. K.
    Shin, D. B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M. P.
    Suarez, T.
    Santamaria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 183S - 183S
  • [43] QUALITY OF LIFE RESULTS FROM A PHASE III STUDY OF TRASTUZUMAB PLUS CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION CANCER
    Ohtsu, A.
    Wang, L.
    Lim, H.
    Gourbounova, V
    Bang, Y.
    Van Cutsem, E.
    Al-Sakaff, N.
    Lehle, M.
    Hill, J.
    de Mendoza, Hurtado F.
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 14
  • [44] Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202
    Endo, Shunji
    Kurokawa, Yukinori
    Gamoh, Makio
    Kimura, Yutaka
    Matsuyama, Jin
    Taniguchi, Hirokazu
    Takeno, Atsushi
    Kawabata, Ryohei
    Kawada, Junji
    Masuzawa, Toru
    Yamamoto, Kazuyoshi
    Kobayashi, Kouji
    Sakai, Daisuke
    Shimokawa, Toshio
    Satoh, Taroh
    ANTICANCER RESEARCH, 2019, 39 (02) : 1059 - 1065
  • [45] Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
    Young Saing Kim
    Sun Jin Sym
    Min Young Baek
    Inkeun Park
    Junshik Hong
    Hee Kyung Ahn
    Jinny Park
    Eun Kyung Cho
    Woon Ki Lee
    Min Chung
    Hyung-Sik Kim
    Jae Hoon Lee
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1267 - 1272
  • [46] Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
    Kim, Young Saing
    Sym, Sun Jin
    Baek, Min Young
    Park, Inkeun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Jinny
    Cho, Eun Kyung
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1267 - 1272
  • [47] A PILOT STUDY OF LOW-DOSE CAPECITABINE PLUS TRASTUZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS OLDER THAN 75 YEARS WITH HER2-POSITIVE ADVANCED GASTRIC CANCER
    Sym, S. J.
    Kim, Y. S.
    Park, I.
    Ahn, H. K.
    Hong, J.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Lee, W. K.
    Chung, M.
    Kim, H. -S.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E67 - E67
  • [48] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [49] A PILOT STUDY OF LOW-DOSE CAPECITABINE PLUS TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS AGED 75 YEARS OR OLDER WITH HER2-POSITIVE ADVANCED GASTRIC CANCER
    Kim, Y. S.
    Sym, S. J.
    Park, I.
    Hong, J.
    Ahn, H. K.
    Park, J.
    Cho, E. K.
    Lee, W. K.
    Chung, M.
    Kim, H. S.
    Lee, J. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E18 - E18
  • [50] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
12345